AstraZeneca’s Brilique (ticagrelor) has been recommended in final guidance, in combination with aspirin for up to a year, as an option to treat adults with acute coronary syndromes (ACS).
NICE has also recommended the treatment as a treatment option for people admitted to hospital with unstable angina.
Professor Carole Longson, NICE Health Technology Evaluation Centre Director, says that evidence shows Brilique is “effective at reducing myocardial infarction (MI) and deaths from cardiovascular causes”.
Every year in England, around 200,000 people are diagnosed with ACS, of whom approximately 75% have unstable angina or Non-ST-segment-elevation myocardial infarction (NSTEMI).
The medication works by reducing or preventing blood clots, so that the flow to the heart muscle can be maintained to prevent further damage. It is licensed for the treatment of people with ACS who are managed medically or who are to undergo percutaneous coronary intervention (PCI) – a procedure to widen narrowed arteries in the heart.
The guidance recommends the use of anti-platelets treatment, in combination with aspirin, as a treatment option in people with STEMI who are to undergo PCI and in people with NSTEMI.
“Today’s guidance, in recommending the use of ticagrelor where clinically appropriate, is an affirmation of that effectiveness and good news for patients with ACS, wherever they live in England and Wales, because it increases the number of treatment options available to them,” said Professor Carole Longson, NICE Health Technology Evaluation Centre Director.